O

Oculis Holding AG
ICEX:OCS

Watchlist Manager
Oculis Holding AG
ICEX:OCS
Watchlist
Price: 2 640 ISK 0.96% Market Closed
Market Cap: 824.6m ISK

Relative Value

There is not enough data to reliably calculate the relative value of OCS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OCS Relative Value
Base Case
Not Available
O
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
Forward
972.2
vs History
vs Industry
Median 3Y
-8
Median 5Y
-9.2
Industry
21.7
Forward
-8.3
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-14.5
Industry
16.7
vs History
vs Industry
Median 3Y
-11.3
Median 5Y
-14
Industry
23.1
vs History
5
vs Industry
6
Median 3Y
4.2
Median 5Y
3.4
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
Forward
924.5
vs History
vs Industry
Median 3Y
-16.2
Median 5Y
-19
Industry
5.5
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-12.4
Industry
13.2
Forward
-10.1
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-12.4
Industry
16.8
Forward
-10.7
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-15.6
Industry
15.9
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-14.1
Industry
19.2
vs History
22
vs Industry
10
Median 3Y
6.1
Median 5Y
4.9
Industry
1.9

Multiples Across Competitors

OCS Competitors Multiples
Oculis Holding AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Oculis Holding AG
ICEX:OCS
1.1B ISK 0 -8.6 -11 -10.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.3B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
262.9B CHF 4.3 27.9 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP 4.9 30.5 109.1 159.7
CH
Novartis AG
SIX:NOVN
212.1B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
260.5B USD 4.1 13.7 9.7 11.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143B USD 2.3 14.6 7.4 10.1
P/E Multiple
Earnings Growth PEG
CH
O
Oculis Holding AG
ICEX:OCS
Average P/E: 24.3
Negative Multiple: -8.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
38%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.7
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
4%
3.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
O
Oculis Holding AG
ICEX:OCS
Average EV/EBITDA: 439.1
Negative Multiple: -11
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
4%
3
UK
AstraZeneca PLC
LSE:AZN
109.1
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.7
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
2%
5
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
O
Oculis Holding AG
ICEX:OCS
Average EV/EBIT: 1 881.5
Negative Multiple: -10.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
159.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.5
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3